These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer]. Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L. Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802 [Abstract] [Full Text] [Related]
4. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis. Gu X, Zhang Y. Ann Palliat Med; 2021 Jul; 10(7):7841-7846. PubMed ID: 34353071 [Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL. Int J Clin Pharmacol Ther; 2024 Mar; 62(3):115-121. PubMed ID: 38263810 [Abstract] [Full Text] [Related]
10. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC. Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663 [Abstract] [Full Text] [Related]
16. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J. Br J Clin Pharmacol; 2023 Jan; 89(1):372-379. PubMed ID: 36001055 [Abstract] [Full Text] [Related]
17. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Crawford J. Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218 [Abstract] [Full Text] [Related]
18. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Crawford J. Drugs; 2002 Aug; 62 Suppl 1():89-98. PubMed ID: 12479597 [Abstract] [Full Text] [Related]